Leqembi starts to deliver for Eisai and Biogen
Three years after its first launch in the US, there are signs that Biogen and Eisai's Alzheimer's Leqembi therapy is gathering sales momentum.
Bayer reveals data behind asundexian's stroke win
Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial.
White House's TrumpRx platform has arrived
The Trump administration's long-promised direct-to-consumer (DTC) sales channel for medicines, TrumpRx, has finally gone live.
Hims & Hers copies Novo Nordisk's new Wegovy pill
Competition has already arrived for Novo Nordisk's Wegovy pill, as telehealth company Hims & Hers launches a compounded version.
Flagship's AI-focused Generate Biomedicines files IPO
Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly asthma drug.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Book your tickets and join the PM Society for the 40th PM Aw...
Tickets are on sale for the 40th anniversary of the PM Awards
The Pharmaceutical Manufacturing and Packaging Congress (PHA...
The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
VuuAI and Amiculum partner to transform content engagement i...
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat
10th Tumor Models Summit San Francisco
Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity